Regeneron Pharmaceuticals 2022 Corporate Investor Presentation

Regeneron Pharmaceuticals' February 2022 corporate presentation for investors, discussing pipeline product candidates including EYLEA, Dupixent, Libtayo, and REGEN-COV, along with clinical development programs and forward-looking guidance. The presentation contains investigational data and material risk disclosures related to regulatory approval, commercialization, and intellectual property matters.